BIIB122 225 mg for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Sep 2024: Trial registered, NCT06602193
  2. 24 Oct 2024: Trial started, NCT06602193

The trials

NCT06602193: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

State
Under way
Phase
Phase 2
People
50 planned
Started
24 Oct 2024
Primary completion
Mar 2027
Arms
BIIB122 225 mg
Results
None posted
  1. 19 Sep 2024: Trial registered
  2. 24 Oct 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.